Helene DeCoste of Boston is a patient in a ground breaking clinical trial, testing whether a drug called Solanezumab can slow down or even prevent Alzheimer's disease. No drug has even come close before, but researchers have never tested patients quite like Helene in quite this way before.
"She is a perfect patient for this trial," said Dr. Reisa Sperling, a physician at Harvard University and the project director of what's called the A4 Study.
Doctors are not telling a majority of their patients diagnosed with Alzheimer's that they have the degenerative brain disease, a new report shows.
The research, conducted by the Alzheimer's Association, involved patients whose Medicare records listed treatments that are specific to Alzheimer's disease.
However, when the researchers asked the patients (or a caregiver as a proxy) if their doctor had informed them that they had the brain-robbing disease, only 45 percent said they had been told so by their doctor.
New research is changing long-held ideas of how our minds age, painting a richer picture of different cognitive skills peaking across a lifetime, with at least one - vocabulary - peaking at a time when many are considering retirement.
If you have a friend or loved one who is battling Alzheimer’s disease, you know just how cruel the illness can be. Today, more than 5 million Americans are living with Alzheimer’s, and its rate of diagnosis is increasing as the baby boomer generation ages. Sadly, there is no cure for the disease and no treatments are effective in slowing its progression. But there is hope.
Recently, the BroadMinded blog highlighted the exciting science emerging from the Roadmap Epigenomics program, resulting in the most comprehensive map of the human epigenome — the collection of chemical changes to DNA and its supporting proteins that help control how genes are turned on or off.
The American Academy of Neurology and the American Brain Foundation are awarding the 2015 Potamkin Prize for Research in Pick's, Alzheimer's and Related Diseases to Peter Davies, PhD, of the Feinstein Institute for Medical Research in Manhasset, NY, and Reisa A. Sperling, MD, of the Brigham and Women's Hospital and Massachusetts General Hospital in Boston.
The ability to recall names and faces with lightning speed may start to fade in one’s 20s, but our capability to perform other functions, such as learning new words, doesn’t peak until decades later, according to a new study by Boston scientists.
A National Institutes of Health-led public-private partnership to transform and accelerate drug development achieved a significant milestone today with the launch of a new Alzheimer’s Big Data portal - including delivery of the first wave of data - for use by the research community. The new data sharing and analysis resource is part of the Accelerating Medicines Partnership (AMP), an unprecedented venture bringing together NIH, the U.S.
Alzheimer's researchers at Harvard for the first time are scanning the brains of healthy patients for the presence of a hallmark protein called tau, which forms toxic tangles of nerve fibers associated with the fatal disease.
The new scans are part of a large clinical trial called Anti-Amyloid Treatment in Asymptomatic Alzheimer's or A4, the first designed to identify and treat patients in the earliest stages of Alzheimer's, before memory loss begins.
Venture capitalists are known for making bold bets on high-risk projects that have the potential for huge payoffs. Today, driven by that vision, a group of business leaders who founded the Cure Alzheimer’s Fund (CAF) to find a cure for this disease are seeing important returns on their investment in research at Mass General and beyond.
The scientific results the CAF support has brought about are nothing short of game changing as Mass General researchers resolve some long-unanswered questions about how Alzheimer’s disease develops.